Overview — Strengthening R&D Leadership in a High-Growth Biotech
Our client, a clinical-stage biotech developing next-generation cell and immunology therapies, needed a senior R&D leader to shape their preclinical and translational strategy — someone with deep cellular biology expertise and broad drug development experience. In a highly competitive market for specialised cell therapy talent, GenSearch designed a focused international search that led to a successful appointment, strengthening our client’s R&D leadership and accelerating portfolio execution.
Client Snapshot
- Geography: Europe with global operations
- Stage: Clinical-stage SME
- Therapeutic Focus: Immune-modulating cell therapies
- Mandate: Head of Non-Clinical Development — R&D leadership, preclinical and translational
Mission
To appoint a scientific leader with the credibility to shape non-clinical strategy and delivery — both as an internal champion and external ambassador.
The Challenge — Competing for Scarce Expertise
Talent Shortage in Cell & Gene Therapy – Rapid growth in cell and gene therapy had outpaced the available pool of experienced non-clinical leaders. Complex Expertise and Multidisciplinary Scope — The mandate demanded a leader with deep immunology knowledge and broad oversight of toxicology, IND-enabling studies, CRO management and translational research. Attracting Pharma Leaders to Agile Biotech Environments — The role required convincing senior pharma experts to transition into a fast-paced, entrepreneurial biotech environment — balancing scientific challenge with agility and risk-taking.
Our Approach — Global Reach, Tailored Insight
Discovery & Alignment with the Leadership Team — We partnered closely with the client to capture their scientific vision, leadership culture and key success factors. International Executive Search Strategy — Using proprietary GenSearch market intelligence, we mapped global talent pools across biotech, pharma and CROs, prioritising individuals with relevant Treg and immunology backgrounds. Employer Value Proposition & Market Positioning – We worked with the leadership team to refine messaging and position the role compellingly in a candidate-driven market.
Implementation Highlights
- Built a target organisation list informed by market intelligence and competitor benchmarking.
- Engaged trusted scientific networks and thought leaders to identify hidden talent.
- Leveraged GenSearch’s global R&D network to access diverse candidates.
- Delivered a balanced shortlist across biotech, pharma, and CRO backgrounds.
- Conducted leadership and culture-fit assessments to evaluate transition readiness.
Results: From Global Mapping to Strategic Appointment
- Engaged candidates across three continents.
- Delivered a diverse shortlist blending biotech, pharma and CRO experience.
- Presented finalists with full non-clinical development ownership: mechanism of action, GLP toxicology, IND packages and CRO oversight.
- Successfully appointed a senior leader now driving non-clinical and translational strategy.
- Ongoing partnership: four further mandates entrusted to GenSearch since this success.
GenSearch Insights
“It was a pleasure to work on such a technically rich mandate. Engaging with world-class scientists who combine rigour, curiosity and vision reminds us why our work matters.” — GenSearch Consultant Team
“GenSearch demonstrated deep market knowledge and exceptional access to talent. The shortlist reflected both scientific excellence and leadership potential. The appointed candidate has made a tangible impact on our R&D organisation.” — Client, Clinical-Stage Biotech
FAQs
Why is non-clinical leadership important for Treg therapies?
Treg therapies are scientifically complex and require deep expertise in immunology, cell biology, translational research and safety assessment. Strong non-clinical leadership helps align the mechanism of action, toxicology package, biomarker strategy and regulatory evidence with the company’s clinical development plan. For clinical-stage biotech companies, this leadership is essential to advance programmes with rigour, speed and credibility.
Why is it difficult to recruit senior Treg and cell therapy leaders?
The talent pool is limited because Treg, immunology and advanced therapy expertise is highly specialised. Demand for experienced cell and gene therapy leaders has grown faster than the available supply, particularly for candidates who combine scientific depth with strategic drug development experience. This makes targeted international executive search essential when hiring senior non-clinical or translational R&D leaders.
How did GenSearch identify candidates for this non-clinical development mandate?
GenSearch built a focused international search strategy using market intelligence, competitor benchmarking and trusted scientific networks. The team mapped relevant talent across biotech, pharma and CRO organisations, prioritising candidates with immunology, Treg, preclinical and translational development experience. This approach enabled the client to access both visible and hidden talent across several regions.
What made this executive search assignment complex?
The mandate required a rare combination of expertise: T-cell biology, immunology, toxicology, IND-enabling studies, CRO management, translational research and senior R&D leadership. The challenge was not only to identify qualified candidates, but also to assess their readiness to lead in a fast-moving clinical-stage biotech environment.
What was the outcome of the search?
GenSearch successfully appointed a senior Head of Non-Clinical Development who is now helping drive non-clinical and translational strategy for the client’s Treg therapy portfolio. Following this successful appointment, the client entrusted GenSearch with four further mandates.
Let’s Talk
If you’re hiring a non-clinical or translational R&D leader and need to balance scientific depth with strategic delivery, GenSearch can help you compete for rare biotech talent. Contact GenSearch to discuss your next leadership search.
